-
Interview: Simplifying Existing Procedure Eases Market Penetration for PhotocurePresident and CEO Kjetil Hestdal discusses the company's photodynamic technology harnessed in Hexvix® and Allumera®. Hexvix®, branded as Cysview® in the U.S., aids in cystoscopy procedures for bladder cancer.06 Jul 2012 -
Photocure strengthens the management teamAnnounces appointment of Chief Finance Officer05 Jul 2012
-
Final transition milestone for Hexvix® achievedA total of EUR 5 million in manufacturing milestones achieved to date18 Jun 2012
-
Presentation and webcast of Visonac® phase 2b results 31 May 15.00 CETAccess to webcast and presentation via this link: http://webtv.hegnar.no/webcast.php?id=6554231 May 2012
-
Photocure announces positive results of phase 2b study evaluating Visonac® in acneResults demonstrate a significant reduction in inflammatory lesions and a significant improvement in overall acne severity.31 May 2012
-
Data presented shows that Hexvix® cystoscopy significantly improves time to recurrence of bladder cancerPhotocure to present data on impact of Hexvix®/Cysview® on long term recurrence rates at American Urological Association annual meeting, Atlanta, GA, USA. The results indicates that Hexvix cystoscopy significantly improves time to recurrence of bladder cancer.22 May 2012
-
Enhanced market access to Cysview® in the US marketPhotocure announces FDA approval of upgraded Karl Storz blue light cystoscope for use with Cysview. This will significantly enhance the market access to Cysview in the US market.07 May 2012
-
Announcement of the 1st Quarter Report 201226 Apr 2012
-
Photocure launches new corporate websitePhotocure has recently launched the new corporate website. It is a flexible and commercial showcase for Photocure’s validated success stories, based on the Photocure Technology®.20 Apr 2012
-
Photocure achieves milestone triggering payment of €750,000Photocure has achieved the third and final manufacturing transition milestone from Ipsen, its new strategic partner for commercializing Hexvix® worldwide, excluding the US and Nordic region. This triggers a payment of EUR 750 thousand.11 Apr 2012
-
Cevira® is easy to administer and shows encouraging early efficacy resultsThe encouraging results from the Cevira® study are being presented today at the American Society of Colposcopy and Cervical Pathology (ASSCP) in San Francisco by Dr. Mark Einstein, Montefiore Medical Center, NY. Cevira® represents a breakthrough technology that integrates the drug and light source into a compact, single-use disposable device, for the treatment of human papilloma virus (HPV) associated diseases of the cervix.15 Mar 2012
-
Photocure achieves milestone triggering payment of € 1.5 millionPhotocure announces today the achievement of the second manufacturing transition milestone from Ipsen, its new strategic partner for commercializing Hexvix® worldwide, excluding the US and Nordic region. This triggers a payment of EUR 1.5 million.05 Mar 2012
-
Hexvix® improves bladder cancer free survival - data to be presented at the EAU congressPhotocure and Ipsen to co-sponsor two symposia on bladder cancer management. Data on impact of Hexvix® on long term recurrence rates to be prestented at European Association of Urology (EAU) Congress, Paris24 Feb 2012
-
Photocure announces new commercial strategy for Hexvix®, the innovative product for improved detection of bladder cancer• Strategic collaboration with Ipsen for marketing rights in Europe and the rest of the world except Nordics and the US • Photocure to commercialise the product directly in the US market27 Sep 2011
-
Photocure Launches Allumera® A New, Dynamic Cosmetic For Achieving Timeless SkinAllumera Represents The First In A New Class Of Photodynamic Cosmetics22 Jun 2011
-
Photocure initiates enrollment into phase II trial of Cevira® for cervical HPV infectionFirst study to evaluate optimal dose of novel integrated drug-delivery device First novel therapeutic treatment option for highly prevalent cervical HPV infections and precancerous lesions22 Jun 2011
